SCHEDULE 13G/A: Major Investor Group Discloses 8.6% Stake in Clearside Biomedical
Beneficial Ownership Report
A group led by Bradford T. Whitmore has disclosed a combined beneficial ownership of 8.6% of Clearside Biomedical, Inc.'s common stock as of December 31, 2024.
Summary
- Bradford T. Whitmore, Grace Brothers, LP, Whitmore Holdings, LLC, and Bradford Whitmore Trust collectively beneficially own 6,523,511 shares of Clearside Biomedical, Inc. Common Stock.
- This aggregate ownership represents 8.6% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 75,843,504 shares of Common Stock outstanding as of November 8, 2024, as reported in the Issuer's Form 10-Q.
- Bradford T. Whitmore serves as the sole trustee of Bradford Whitmore Trust and the manager of Whitmore Holdings, LLC.
- Whitmore Holdings, LLC is the general partner of Grace Brothers, LP.
- Bradford T. Whitmore and Bradford Whitmore Trust share voting and dispositive power over all 6,523,511 shares.
- Whitmore Holdings, LLC has sole voting and dispositive power over 4,268,969 shares and shared power over 2,254,542 shares held by Grace Brothers, LP.
- Grace Brothers, LP has sole voting and dispositive power over 2,254,542 shares.
Sentiment
Score: 6
Explanation: The filing indicates a substantial passive ownership stake by a group of related entities, which can be interpreted as a vote of confidence in the company, though it provides no operational or financial updates.
Positives
- The disclosure of a significant beneficial ownership stake (8.6%) by a group of related entities, including an individual investor and associated trusts/LLCs, can signal confidence in Clearside Biomedical, Inc.'s long-term prospects.
Future Outlook
This document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the Issuer's future outlook.
Industry Context
This Schedule 13G filing is a routine disclosure of a significant ownership stake by an investor group in a publicly traded company. It does not provide specific industry trends or competitive analysis, but the presence of a substantial passive investor can be a factor in market perception within the biotechnology sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant ownership stake by a single investor group may be viewed positively, potentially indicating long-term interest and stability in the shareholder base.
Key Dates
| Date | Description |
|---|---|
| November 8, 2024 | Date as of which 75,843,504 shares of Clearside Biomedical, Inc. Common Stock were outstanding. |
| November 12, 2024 | Date Clearside Biomedical, Inc. filed its Form 10-Q for the quarter ended September 30, 2024. |
| December 31, 2024 | Date of event which requires the filing of this Schedule 13G statement. |
| March 4, 2025 | Date the Schedule 13G Amendment No. 6 was signed and filed. |
Keywords
Clearside Biomedical, CLSD, Schedule 13G, Beneficial Ownership, Bradford T. Whitmore, Grace Brothers LP, Whitmore Holdings LLC, Bradford Whitmore Trust, Equity Stake, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.